


IMB DX

www.imbdx.com



IMB Dx has a range of liquid biopsy solutions that makes it easy to detect cancerous tumors with a simple blood test. Surgical biopsies are no longer needed, and monitoring a tumor over time is as simple as taking follow-up blood tests.



Cancer Diagnosis Often Comes Too Late

Early detection of cancer can increase survival rates by up to 50 percentage points. However, this is difficult to do. Current cancer diagnoses heavily rely on CT or MRI tests, and the cancer may already be in an advanced stage by the time doctors advise a scan. Surgical tissue biopsies can also detect cancer, but come with drawbacks such as patient side-effects or even insufficient sample sizes. Tissue biopsies are also unable to identify the entire mutation profile of a tumor, leaving doctors unable to make a diagnosis with absolute confidence.

A New Paradigm Shift in Cancer Diagnosis

AlphaLiquid, developed by IMB Dx, is a minimally invasive liquid biopsy method which requires only a single blood test to get results and is superior to solid tissue biopsies in many ways: It can detect cancer earlier than any other method, identify the entire mutation profile of a tumor in one shot, and find the cause of cancer for each patient. This allows doctors to suggest a personalized therapy strategy for each individual patient and monitor the patient's ongoing status with follow-up tests.

An Emerging Multi-billion Dollar Market

There is a large market potential for liquid biopsy technology. Globally, it's worth over 20 billion USD with a CAGR of over 50% within three years. The Asia and Europe market combined will be worth 10 billion USD combined within three years. IMB Dx is aiming for at least 20 million USD of this market by 2024.

Strengths in Analytics and Detection

While we have many competitors in this emerging market, IMB Dx is very competent at analytics and detection. They can analyze over 100 tumor related genes with just one test, while competitors can manage just 75 or fewer. They can also detect fusion variations and copy number variations with a high degree of accuracy, which is very difficult to do with DNA.

The AlphaLiquid Series

IMB Dx are able to provide a detailed clinical report based on AlphaLiquid tests within just 10 working days. They offer a portfolio of three AlphaLiquid products, each with unique features.

- AlphaLiquid 100 is capable of identifying mutations from cancer in 106 cancer-related genes.
- AlphaLiquid 1000 covers over 1000 cancer-related genes and is used to monitor tumors.
- AlphaLiquid Screening can detect cancer in early stages.

Milestones

AlphaLiquid is under review for approval with the Korean FDA, CE and CAP, and is the first product of its type in Korea. Direct sales to two major Korean hospitals will begin from Q4 this year. This will enable the collection of cell-free DNA samples from 10,000 patients to demonstrate clinical efficacy of AlphaLiquid.

Team

Three of the four team leaders of IMB Dx are professors at prestigious Korean universities, and their CEO has a senior management business background. In 2014, they began researching together about circulating tumor DNA and the clinical applications of liquid biopsies. They founded IMB Dx in 2018 based on the promising results of these studies and have since attracted almost USD 10 million in funding to date, including their Series A in April, 2020.

